Difference between revisions of "Lapatinib (Tykerb)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
Warner-admin (talk | contribs) |
||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Breast cancer]] | + | *[[Breast cancer, HER-2 positive|HER2+ breast cancer]] |
==Patient drug information== | ==Patient drug information== | ||
| Line 18: | Line 18: | ||
* 3/13/2007: Initial FDA approval "in combination with [[Capecitabine (Xeloda) | capecitabine]], for the treatment of patients with advanced or metastatic [[Breast cancer | breast cancer whose tumors overexpress HER2]] and who have received prior therapy including an [[:Category:Anthracyclines | anthracycline]], a [[:Category:Taxanes | taxane]], and [[Trastuzumab (Herceptin) | trastuzumab]]." | * 3/13/2007: Initial FDA approval "in combination with [[Capecitabine (Xeloda) | capecitabine]], for the treatment of patients with advanced or metastatic [[Breast cancer | breast cancer whose tumors overexpress HER2]] and who have received prior therapy including an [[:Category:Anthracyclines | anthracycline]], a [[:Category:Taxanes | taxane]], and [[Trastuzumab (Herceptin) | trastuzumab]]." | ||
* 1/29/2010: New indication "in combination with [[Letrozole (Femara) | letrozole]] for the treatment of postmenopausal women with [[Breast cancer | hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor]] for whom hormonal therapy is indicated." | * 1/29/2010: New indication "in combination with [[Letrozole (Femara) | letrozole]] for the treatment of postmenopausal women with [[Breast cancer | hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor]] for whom hormonal therapy is indicated." | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Brand name:''' Tykerb | ||
==References== | ==References== | ||
| Line 23: | Line 26: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| + | [[Category:Protein expression-specific medications]] | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
[[Category:EGFR inhibitors]] | [[Category:EGFR inhibitors]] | ||
[[Category:ERBB2 inhibitors]] | [[Category:ERBB2 inhibitors]] | ||
| − | |||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
[[Category:Drugs FDA approved in 2007]] | [[Category:Drugs FDA approved in 2007]] | ||
Revision as of 00:18, 27 October 2017
General information
Class/mechanism: EGFR/HER2 tyrosine kinase inhibitor; 4-anilinoquinazoline inhibitor of the intracellular tyrosine kinase domains of EGFR (epidermal growth factor receptor/ErbB1) and HER2 (human epidermal growth factor receptor 2/ErbB2), which drive proliferation in certain malignancies.
[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Lapatinib (Tykerb) patient drug information[4]
- Lapatinib (Tykerb) patient drug information (Chemocare)[5]
- Lapatinib (Tykerb) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 3/13/2007: Initial FDA approval "in combination with capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab."
- 1/29/2010: New indication "in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated."
Also known as
- Brand name: Tykerb